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DIFFERENTIATING BETWEEN THE TUMOR MICROENVIRONMENT AND 
INFLAMMATION IN ORDER TO USE IMMUNE CELLS AS LIVING CELL 
DIAGNOSTICS FOR EARLY CANCER DETECTION 
SANDHYA BODAPATI 
ABSTRACT 
 Recent advances in the field of synthetic biology have enabled the use of 
macrophages as living cell diagnostics for early cancer detection. Presently, macrophages 
have been engineered to be macrophage sensors, which produce a reporter signal upon 
activation of the ARG1 promoter—an event which will occur in the tumor 
microenvironment (Aalipour et al., 2019). Incorporation of Boolean logic gates can help 
refine the specificity of this sensor, to ensure that it is only activated in the tumor 
microenvironment and not in inflammatory or wound healing environments. In order to 
do this, it is necessary to identify genes that can be used as markers that are differentially 
specific to tumor microenvironments compared to inflammatory microenvironments. 
Because tumor microenvironments are commonly infiltrated with M2-polarized 
macrophages and inflammatory environments are commonly infiltrated with M1-
polarized macrophages, assessing relative gene expression from M1 and M2 type 
macrophages could be a useful avenue for identifying genes to be used in Boolean logic 
gates for enhancing the specificity of the previously developed macrophage sensor. First, 
macrophages must be polarized to the M1 and M2 phenotypes, and second, quantitative 
real time PCR must be used to identify genes that are upregulated in either M1s or M2s. 
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INTRODUCTION 
  Cancer is a leading cause of death around the world, despite numerous advances 
in this field of medicine in the past century (Shamsi & Islamian, 2010). Early detection of 
cancer cells would revolutionize the way cancer is treated, and save millions of lives and 
resources invested into healthcare. While early detection may sound like a simple task, 
early identification of cancer cells is challenging for various reasons. There is typically a 
gap of years between the inception of the first neoplastic cells in one’s body and the time 
that they are detectable by clinical imaging. (Shamsi & Islamian, 2010). In fact, 
mathematical models have calculated this period of preliminary growth before tumor 
cells can be imaged clinically (Hori, Lutz, Paulmurugan & Gambhir, 2017). Tumors must 
be at a size of 6.24 mm to be detected with clinical imaging, and this size is reached 
approximately 50 months following the birth of asymptomatic tumor cells (Hori, Lutz, 
Paulmurugan & Gambhir, 2017). This model is shown in Figure 1. 
 
The Need for Early Cancer Detection 
 More often than not, in clinics today, cancer is identified in stages III and IV, and 
by this point, though doctors try to limit the spread of metastases, success rates are low 
(Shamsi & Islamian, 2010). The earlier cancer is detected, the more likely there is a 
chance of a positive treatment outcome. The medical community still lacks the 
technology to detect the first few divisions of neoplastic cells in a noninvasive manner, 
before they metastasize throughout the body (International Atomic Energy Agency, 
2010). Blood tests are widely used clinically to assess the levels of cancer biomarkers 
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from tumors and the severity of cancer, but this does not address preventative care; 
further research is needed to apply this principle to preventative stages, in order to 
identify the conception of the first tumor cells in one’s body (Shamsi & Islamian, 2010). 
 
Figure 1. Applying a mathematical model to measure the growth of an 
asymptomatic tumor. Plasma biomarker levels were measured using blood tests every 3 
months until the tumor was detectable with imaging. While timage reflects imaging 
detectability, dimage reflects estimated tumor diameter based on the plasma biomarker 
level. Figure taken from (Hori, Lutz, Paulmurugan & Gambhir, 2017). 
 
Applications of Synthetic Biology for Early Diagnosis 
The field of synthetic biology paves way for the use of living cell diagnostic 
techniques for early cancer detection (Sedlmayer, Aubel, & Fusseneger, 2018). Synthetic 
biology refers to the use of genetic engineering principles to modify existing circuitry in 
cells and microorganisms to produce a desired function or response. Synthetic biology 
has huge applications in the field of early disease detection. For example, a sensor that 
monitors levels of histamine release in the body by producing a reporter protein upon 
histamine detection has allowed for sensitive and easy monitoring of allergens and 
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allergic disorders in sensitive patients (Auslander et al., 2014). Modification of 
microorganisms such as Salmonella typhi by manipulation of quorum-sensing and 
autoinduction has been applied to early cancer detection and even treatment via antitumor 
drug release (Din et al., 2016). The use of synthetic biology to engineer living cells and 
other sensors for early detection of disease demonstrates key advantages to traditional 
blood-based biomarker analysis due to the sensitivity of genetic approaches to disease 
detection. Living cell diagnostics can detect disease at its conception, thereby serving as a 
method for monitoring a patient’s health. Furthermore, living cell diagnostics can identify 
disease even before it is detectable through clinical blood tests, which leads to better 
patient prognosis.   
However, in the context of cancer, several challenges remain with regards to first 
identifying genes and promoters that are specific to the tumor microenvironment in order 
to then apply concepts of synthetic biology for early detection. Most importantly, the 
tumor microenvironment is often described as a case of chronic inflammation (Yang and 
Zhang, 2017). It is well known that areas demonstrating wound healing or inflammation 
are particularly prone to tumor formation, as in the frequently documented case of 
inflammatory bowel disease progressing to colon cancer, for example. On a molecular 
level, even the growth factors and immune cells involved in inflammatory and tumor 
microenvironments are similar. For example, fibrin deposition caused by vascular 
endothelial growth factor (VEGF) release is a key initial stage in wound healing as well 
as solid cancer formation (Dvorak, 2015). Furthermore, both inflammatory environments 
and tumor microenvironments are characterized by a high density of leukocytes (Yang 
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and Zhang, 2017). Clearly, isolating the tumor microenvironment through genetic 
targeting and application of synthetic biology proves to be a challenging task when 
keeping in mind the need for specificity and sensitivity in early cancer detection. 
 
Boolean Logic Gates 
Luckily, the synthetic biology-based technique of incorporating Boolean logic 
gates into biological sensors can help to refine diagnostic tools by manipulating cell 
signaling pathways (Wang and Buck, 2012). For example, the incorporation of a Boolean 
“AND” gate in an engineered synthetic cell circuit can ensure that a reporter is only 
produced when two inputs are present, as shown in Figure 2 (Wang and Buck, 2012). 
The incorporation of a “NOT” gate can repress reporter release in the presence of other 
defined inputs (Wang and Buck, 2012). Boolean logic has been applied to many 
biological models, including a circuit designed for the detection and treatment of 
psoriasis (Schukur, Geering, Charpin-El Hamri, & Fussenegger, 2015). Thus, in regards 
to creating a biosensor that only detects the tumor microenvironment and not 
inflammatory environments, incorporation of Boolean logic gates in synthetic gene 
circuits could prove to be a successful route. 
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Figure 2. Schematic depicting the use of Boolean logic gates to improve the 
specificity of an engineered cell circuit. An “AND” logic gate helps define when a 
reporter signal should be produced, and a “NOT” logic gate outlines parameters where a 
reporter signal should not be produced (Wang and Buck, 2012). 
 
Luciferase Reporters 
 Secreted reporters pose as a useful method for monitoring activation of a 
promoter in cell culture media and in vivo because their expression can be quantified 
without cell lysis (Tannous, 2009). Reporter gene transcription corresponds with 
promoter activation, meaning that the level of secreted protein generally matches 
intracellular mRNA levels. Luciferase reporters code for oxidative enzymes that generate 
quantifiable bioluminescence (Tannous, 2009). Gaussia luciferase (Gluc) can also be 
detected intracellularly: approximately 5% of the reporter protein is not secreted, 
allowing for the use of bioluminescence imaging (Aalipour, 2019). This secreted reporter 
is from the marine organism Gaussia princeps, and can be detected in small microliter 
volumes of cell culture media, blood, and urine through the use of highly sensitive assays 
(Tannous, 2009).  
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Immunology and Cancer 
 Cancer immunotherapy is a rapidly growing field of modern medicine. 
Traditional cancer therapy entailed use of surgery, radiation, and chemotherapy. Today, 
these techniques can now be used in combination with immunotherapies such as chimeric 
antigen receptor (CAR) T-cells, in order to reduce the amount of cytotoxic side effects 
caused by traditional cancer treatments. CAR T-cell therapy represents a form of 
adoptive cell transfer because a patient’s own T-cells are isolated, genetically modified, 
and replaced in the patient (Miliotou & Papadopoulou, 2018). In the case of CAR T-cells, 
the immune cells are engineered to express receptors specific for antigens produced by 
the patient’s tumor cells, allowing for a highly personalized and precise form of 
immunotherapy (Miliotou & Papadopoulou, 2018). One major drawback of CAR T-cell 
therapy is that it is primarily only effective in hematologic cancers, and is not yet 
efficacious in solid tumors (Klichinsky et al., 2017). 
 Recently, use of macrophages in cancer immunotherapy has become a novel area 
of interest. Macrophages are a natural waste-product during the isolation of a patient’s T-
cells during CAR T-cell therapy, and thus making use of them for alternate anticancer 
treatment modalities that can be used in conjunction with CAR-T cell therapy is 
promising (Moyes et al., 2017).  Furthermore, macrophages exhibit excellent tumor-
homing behaviors, and would be primarily effective in targeting solid cancers because of 
their ability to efficiently penetrate tumors and accumulate there (Alvey et al., 2017). 
Finally, as antigen presenting cells (APCs), macrophages will engulf tumor cells and 
present tumorigenic antigens, a process which activates T-cell response and helps induce 
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the body’s natural immune response (Klichinsky et al., 2017). In fact, CAR macrophages 
(CARMA) have been developed as a way to engineer macrophages to phagocytose tumor 
cells (Klichinsky et al., 2017). Following the same principles of CAR T-cell therapy, 
CARMAs are also engineered to express antigens specific to a patient’s tumor 
(Klichinsky et al., 2017).  
Genetically engineered macrophages (GEMs) are another avenue for use of 
macrophages in cancer immunotherapy (Moyes et al., 2017). The main purpose of GEMs 
is to alter the tumor microenvironment into an immunologically active state (Moyes et 
al., 2017). For example, macrophages are engineered to express proteins such as 
interleukin (IL) 21 that directly promote immune cell activation or indirectly prevent 
suppression of immune cell activity (Moyes et al., 2017). In this case, genetic engineering 
of macrophages is produced through the use of lentivirus transduction, a novel feat given 
the fact that macrophages naturally produce a restriction factor called SAMHD1, thereby 
traditionally preventing them from lentivirus transduction (Moyes et al., 2017). Inclusion 
of viral protein X in the lentivirus packaging allowed for the degradation of SAMHD1 
and stable genetic delivery to human macrophages (Moyes et al., 2017). 
 Another approach to using macrophages for cancer immunotherapy comes 
through manipulation of SIRPα, a macrophage surface-protein that serves as a checkpoint 
for the CD47 marker, a “don’t eat me” signal for macrophages (Alvey et al., 2017). 
Because tumor cells upregulate CD47, they are able to evade macrophage phagocytosis 
through the SIRPα pathway (Alvey et al., 2017). Upon injecting SIRPα-inhibited 
macrophages into mice, tumor regression was observed, suggesting how manipulation of 
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macrophage signaling pathways can pose as a potential pathway for new cancer 
treatments (Alvey et al., 2017).  
 While it is evident that immune cells and macrophages, specifically, have a 
growing role in cancer therapies, use of immune cells for cancer diagnostics is a less-
explored field despite the cell type’s natural tumor homing abilities.  
 
A Novel Field: Use of Immune Cells for Cancer Detection 
 There is certainly a precedent for using living cell diagnostics for cancer detection 
(Danino et al., 2015). Many strains of bacteria demonstrate natural tumor homing 
abilities, primarily due to hypoxia and other features of the tumor metabolic environment, 
and are therefore convenient candidates for cancer detection (Danino et al., 2015). For 
example, using principles of synthetic biology, the Escherichia coli Nissle 1917 strain 
was engineered to produce a reporter detectable in urine upon homing to liver tumors 
(Danino et al., 2015). By using principles of synthetic biology, the use of living cell 
diagnostics can be expanded to include immune cells and specifically, macrophages, for 
early cancer detection with clinical translatability. Furthermore, administering immune 
cells such as macrophages has the added benefit that the immune cells will help destroy 
tumors when they detect an early cancer.  
 
Macrophage Biology 
 Macrophages are part of the body’s innate immune system, serving as 
phagocytotic cells and part of the body’s first line of defense to pathogens and disease 
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(Parisi et al., 2018). While tissue-resident macrophages develop in utero and remain 
throughout one’s life, recruited macrophages develop throughout life from hematopoietic 
stem cells and circulate as monocytes until they are recruited to specific tissues (Parisi et 
al., 2018). The proliferation and survival of recruited macrophages depends on activation 
of the colony stimulating factor 1 receptor (CSF-1R) on macrophages which binds both 
macrophage colony stimulating factor (M-CSF) and IL-34 (Garceau et al., 2010).  
Once recruited to a specific microenvironment, macrophages further “activate” or 
mature to adopt a specific phenotype based on various metabolic and other biological 
stimuli in the environment due to their high level of plasticity (Martinez & Gordon, 
2014). Traditionally, a dichotomy for macrophage polarization has been suggested: 
classically activated macrophages representing a “killer” or proinflammatory state are 
termed “M1s”, and alternatively activated macrophages represent a “builder” or anti-
inflammatory state are termed “M2s” (Parisi et al., 2018). Each phenotype has a distinct 
metabolic profile and secretes unique cytokines to induct killer or builder pathways, as 
depicted in Figure 3 (Parisi et al., 2018). Both phenotypes have roles in fighting against 
parasitic infections, and depending on the type of parasite and stage of disease, 
macrophages may polarize more towards one phenotype or another (Liu et al., 2014). For 
example, classically activated macrophages have microbicidal properties due to the 
upregulation of proinflammatory cytokines such as Interferon-γ (IFNγ), as well as the 
increase in reactive oxygen species (ROS) and nitrogen radicals caused by the induction 
of genes such as inducible nitric oxide synthase (iNOS) (Liu et al., 2014). On the 
contrary, alternatively activated macrophages are key players in fighting helminth 
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infections, and also have regulatory and wound-healing roles due to the release of 
immunosuppressive cytokines such as IL-10 , which are important for wound resolution 
(Liu et al., 2014).  
However, it has become apparent that the M1 and M2 dichotomy is too simple to 
encompass the different forms of activated macrophages. For example, tumor associated 
macrophages (TAMs) are macrophages containing different levels of both M1 and M2 
properties depending on their spatial location in a tumor’s metabolic environment 
(Carmona-Fontaine et al., 2017). The general scientific consensus is that TAMs are M2-
like macrophages (Carmona-Fontaine et al., 2017). Tumors tend to recruit TAMs and 
M2s in order to generate an immunosuppressive environment that allows for tumor 
growth (Parisi et al., 2018).  
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Figure 3. A few macrophage polarization outcomes and their transcriptional 
profiles. Note how stimuli and gene expression are not completely specific to a given 
macrophage phenotype. This figure does not represent a complete list of stimuli for 
macrophage polarization nor a complete list of genes upregulated in each phenotype. 
Figure adapted from (Parisi et al., 2018). 
 
The different signaling pathways and features that drive macrophages to 
inflammatory and tumor microenvironments are important to consider in order to 
engineer macrophages using principles of synthetic biology as living cell diagnostics. 
While most cancer therapies utilize M1s to produce an anticancer effect, cancer detectors 
will mainly utilize M2s or TAMs because of their tumor homing nature.  
 
Arginase 1 
Upregulation of Arginase 1 (ARG1) is a marker of M2 macrophages, and 
therefore of TAMs, which are M2-like (Liu et al., 2014). In the liver, ARG1 codes for a 
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key metabolic enzyme involved in the final stage of the urea cycle where it converts L-
arginine to urea and L-ornithine (Pauleau et al., 2014). ARG1 is also upregulated in 
hematopoietic cells including M2 polarized macrophages where its function is less 
understood (Pauleau et al., 2014). Studies suggest that in M2s, the enzyme consumes the 
substrate arginine, thereby depleting its availability for nitric oxide synthases (Pauleau et 
al., 2014). Furthermore, secondary metabolites such as L-ornithine can be used for 
collagen biosynthesis (Pauleau et al., 2014).  
The ARG1 promoter is ultimately activated by STAT6 activity (Pauleau et al., 
2014). STAT6 is activated by cytokines such as IL4 and IL13, but it should be noted that 
IL4 and IL13 do not directly activate the ARG1 promoter (Pauleau et al., 2014). Three 
transcription factors are necessary for ARG1 promoter activation: PU.1, C/EβP, and 
STAT6 (Pauleau et al., 2014). The promoter does include an enhancer element that is IL4 
responsive, but presence of the enhancer is not enough to trigger ARG1 expression 
(Pauleau et al., 2014). It should be noted that regions upstream of the transcriptional start 
site are constitutively active, indicating that the ARG1 promoter is “leaky” and will 
constantly be generating some amount of signal (Aalipour et al., 2019).  Thus, fold 
changes in luminescence should be measured relative to baseline promoter activation in 
luciferase reporter assays.  
 
Proof of Concept Macrophage Sensor 
In a proof of concept study, macrophages have been used as immune cell sensors 
in mice to detect tumors as small as 4 mm3, thereby indicating that the macrophage 
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sensor is able to identify the early cancers that have potential to cause harm to the 
organism (Aalipour et al., 2019). In this model, macrophages are engineered to activate 
upon reaching a tumor metabolic environment, by activating the ARG1 promoter 
(Aalipour et al., 2019). Macrophages were transfected with a plasmid where activation of 
the ARG1 promoter is necessary for release of Gluc, the reporter signal. Because ARG1 
gene expression is upregulated in M2s, the macrophage sensor is activated in the tumor 
microenvironment (Aalipour et al., 2019). Because Gluc is retained intracellularly in the 
macrophages and released into the blood, blood can be assayed to check for sensor 
activation through presence of Gluc, and subsequently, the tumor can be localized 
through bioluminescence imaging (Aalipour et al., 2019). See Figure 4 for a general 
scheme of this proof of concept macrophage sensor.   
 
  
Figure 4. Schematic for the use of macrophages as living cell diagnostics. Engineered 
macrophages would be injected intravenously in vivo (1), and upon homing to tumors 
would activate and release a reporter signal that is detectable in blood (2).  
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Improvements for the Macrophage Sensor 
Techniques of synthetic biology must be applied to make the macrophage sensor 
more specific for cancer detection. When applied in vivo, the macrophage sensor homes 
to confounding disease sites—mainly wound healing (Aalipour et al., 2019). In a mouse 
model of inflammation created with turpentine-oil in the hind leg, the macrophage sensor 
showed an increase in activation during the resolution phase of the wound healing 
process which generally begins on approximately day seven (Aalipour et al., 2019). The 
macrophage sensor did not show as much activation during the initial phase of wound 
healing, which is hallmarked by acute inflammation (Aalipour et al., 2019). During acute 
inflammation, macrophages are activated to be in an M1 state, whereas during resolution, 
the building phenotype, M2, is more prominent. Thus, it is understandable why there is 
false reporting by the macrophage sensor during the resolution phase of wound healing. 
In order for this macrophage sensor to become an ideal tool for detecting and 
monitoring cancer, it must have sensitivity and specificity for small tumors. In other 
words, it must only produce a reporter signal in the presence of a tumor and not in other 
disease states.  
 
Specific Aims 
The goal of this thesis is to first polarize macrophages to the M1 and M2 
phenotypes, in order to pave the way for analyzing genes upregulated in each phenotype. 
The purpose of genetic analysis is to identify genes that are solely upregulated in M1s 
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and not M2s and vice versa, with the hope of eventually incorporating these genes as 
“AND” and “NOT” gates in the macrophage sensor.  
In this thesis, first, murine macrophage cells will be used to activate macrophages 
into the M1 and M2 phenotypes. In order to confirm that the polarization was successful, 
quantitative polymerase chain reaction (qPCR) or real-time reverse transcriptase PCR  
(RT-PCR) will be conducted to monitor for expression of ARG1 and iNOS genes, with 
ARG1 being a marker for M2 polarization and iNOS being a marker for M1 polarization. 
This polarization protocol will then be adapted for human monocyte cells as well, to 
ensure that the genes identified based on genetic analysis for logic gates will eventually 
be clinically translatable. To confirm that human macrophages have been polarized 
appropriately, regular PCR, ELISAs, and qPCR will be conducted to confirm gene 
expression of C-X-C motif chemokine 11 (CXCL11) and TNFα for the M1 phenotype, 
and gene expression of IL-10 for the M2 phenotype (Stossi, Madak-Erdogan, & 
Katzenellenbogen, 2012).  
 16 
METHODS 
 
Macrophage Cell Lines 
 
 To model murine macrophage cells, RAW264.7 cells were obtained from the 
American Type Culture Collection (ATCC). Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% antibacterial-
antimycotic solution (ThermoFisher). Cells were maintained in a humidified 5% CO2 
incubator at 37 °C. Cells are mostly adherent cells, and therefore best scraped off the 
flask using a cell scraper between passages. Cells were maintained at a density between 
approximately 3x106 and 4x106 cells/mL. See Figure 5 for typical RAW264.7 
morphology.  
 
 
Figure 5. RAW264.7 cells viewed with a 400x optical microscope. These cells adopt a 
small and round morphology, but tend to grow in clusters. These cells grow well when 
maintained at a relatively high density. Figure taken from (Kang et al., 2010). 
 
To model human monocyte cells, the THP-1 cell line was obtained from the 
ATCC. The culturing protocol was adapted from the Bowdish Lab, McMaster University, 
Ontario, Canada. Cells were cultured in RPMI supplemented with 10% FBS and 1% 
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antibacterial-antimycotic solution. Additionally, 2-mercaptoethanol (ThermoFisher) was 
added to media while passaging cells in order to reach a final concentration of 0.05 mM 
to help maintain a reducing environment (Bowdish, 2011). These suspension cells were 
maintained at a density between 1x105 and 1x106 cells/mL (Bowdish, 2011). 
In order to activate macrophages into M1 and M2 polarized macrophages, 
cytokines must be added to the culture media. Because the RAW264.7 cells are murine 
macrophages, just 24 hours after plating the cells, cytokines can be added to the media in 
order to activate the macrophages to the M1 and M2 phenotypes. On day one, 1x106  
RAW264.7 cells are plated in 6-well plates in 2.5 mL media. After 24 hours of 
incubation, murine macrophage cells are activated to the M1 and M2 state by adding 
cytokines to the media or replacing the media with tumor conditioned media (TCM) in 
the 6-well plates. To generate M1s, IFNγ was added to reach a final concentration of 100 
ng/mL and to generate M2s, IL4 and IL13 were added in combination at a concentration 
of 25 ng/mL for each cytokine. IL4 and IL13 are key factors involved in immune 
suppression, whereas IFNγ triggers immune cell responses to viral and bacterial 
infections (Martinez & Gordon, 2014). Macrophages were incubated in TCM to generate 
TAM phenotypes. TCM was collected from the murine carcinoma cell line, CT26 
(ATCC). To prepare TCM, 2.5x105 CT26 cells were plated in 6-well plates with 2.5 mL 
media per well. After 24 hours of incubation, the media was extracted and centrifuged for 
10 minutes at 300 g. The supernatant was then used as TCM and was incubated with the 
macrophage cells. The 6-well plates were allowed to incubate for 24 hours with the 
cytokines or TCM for activation to occur. Thus, obtaining polarized murine macrophages 
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required a total of 48 hours, in order to first plate the macrophage cells and subsequently 
polarize them appropriately.  
On the other hand, because the THP-1 cell line is a human monocyte cell line 
rather than a macrophage cell line, these cells must first be changed into macrophages 
before they can be further polarized. THP-1 cells were plated in T25cm2 cell culture 
flasks (Corning) with 1x106 cells in each flask, and 5 mL RPMI media. After 24 hours of 
incubation, the suspension monocyte cells were induced to become adherent macrophage 
cells by addition of phorbol myristate acetate (PMA) (Sigma-Aldrich) at a concentration 
of 100 ng/mL (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012). After 24 hours of 
incubation with PMA, media was changed to fresh RPMI without PMA, and cells were 
allowed to incubate for six more days (Stossi, Madak-Erdogan, & Katzenellenbogen, 
2012). During this six day incubation period, cells were washed and passaged three times, 
or in other words, media was changed every two days (Stossi, Madak-Erdogan, & 
Katzenellenbogen, 2012). After six days of incubation as adherent cells, the unpolarized 
activated macrophages, termed to be in the “M0” state, were ready for activation. To 
generate M1s, LPS was used alone at a concentration of 100 ng/mL or used in 
combination with IFNγ (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012). When 
added in combination, LPS was added to reach a final concentration of 100 ng/mL and 
IFNγ to reach a final concentration of 20 ng/mL (Stossi, Madak-Erdogan, & 
Katzenellenbogen, 2012). LPS and IFNγ were allowed to incubate with the cells for 4 
hours only (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012). LPS binds to the CD14 
receptor on macrophages and triggers the release of cytokines and subsequent immune 
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inflammatory response (Sharp, 2013). To generate M2s, IL4 and IL13 were added in 
combination for a 24 hour incubation period, and were both used at a final concentration 
of 100 ng/mL (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012). See Figure 6 for 
typical morphology of THP-1 cells under different treatment conditions. For incubating 
with the human macrophage cells, TCM was collected from the human cervical cancer 
cell line, HeLa (ATCC), and was prepared by plating 5x106 HeLa cells the day before it 
was used as TCM for macrophage activation. TCM was prepared following the same 
method as for murine macrophage activation.  
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Figure 6. THP-1 cells viewed with a 200x optical microscope under different 
treatment conditions. Addition of PMA causes the macrophages to become adherent 
and responsive to cytokine activation. The scale bar represents 50 µm. Figure taken from 
(Chimal-Ramirez, Espinoza-Sanchez, Chavez-Sanchez, Arriaga-Pizano, and Fuentes-
Panana, 2016). 
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For both cell lines, M0 macrophages were also created by following the same 
protocols for murine and human polarized macrophages but without the addition of any 
cytokines or TCM to their incubation media.  
 
RNA Expression Analysis  
The 6-well plates were centrifuged for 5 minutes at 300 x g, and media 
supernatant was removed from all wells. Qiazol lysis reagent was added to the cell pellets 
and saved in Eppendorf tubes (Qiagen). RNA extraction was conducted using the Direct-
zol RNA Miniprep Kit and protocol (Zymo Research). 
 RNA yield was assessed using the NanoDrop One Microvolume UV 
Spectrophotometer (ThermoFisher). 1000 ng of extracted RNA was used to make cDNA, 
using the iScript cDNA synthesis kit and protocol in 20 µL reactions (Bio-Rad). All 
thermal cycling was conducted using the CFX96 Real-Time System C1000 Touch 
Thermal Cycler (Bio-Rad). For cDNA synthesis, the following protocol was used: 25°C 
for 5 min, followed by 46°C for 20 min, and finally, 95°C for 1 min.  
 The 2x SsoAdvanced Universal Probes Supermix (Bio-Rad) was used to conduct 
qPCR reactions for assessing  iNOS, ARG1, and GAPDH expression in activated murine 
macrophages, and IL-10 expression in activated human macrophages. The volume of 
each qPCR reaction was 20 µL, consisting of 2 µL of cDNA synthesized from the iScript 
cDNA synthesis reactions, 10 µL of SsoAdvanced Universal Probes Supermix, 1 µL of 
FAM fluorophore-conjugated hydrolysis probes for either ARG1, iNOS, or 
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glyceraldehyde 3-phoshate dehydrogenase (GAPDH), and 7 µL of nuclease-free water. 
All reactions were plated in duplicate on a clear-bottom 96-well plate (Bio-Rad). All 
products, including the gene-specific hydrolysis probes were obtained from Bio-Rad. 
Negative control reactions were conducted by replacing the 2 µL of cDNA with 2 µL of 
nuclease-free water. Thermal cycling was conducted at 95°C for 3 min, followed by 60 
cycles of 95°C for 15 seconds and 59°C for 30 seconds. CFX Manager Software Version 
3.1 was used to automatically generate a single cycle threshold and subsequent 
quantitation cycle (Cq) values. Baseline subtraction was conducted for target gene 
expression relative to GAPDH. The Pfaffl method was used for relative quantification of 
gene expression for the different macrophage activation treatment conditions (Pfaffl, 
2001).  
 The 2x ddPCR Supermix for Probes (Bio-rad) was used to conduct PCR reactions 
to assess CXCL11 expression in activated human macrophages. The volume of each PCR 
reaction was 25 µL, consisting of 2 µL of cDNA, 12.5 µL of 2x ddPCR Supermix for 
Probes, 1 µL each of forward and reverse primers for CXCL11, and 8.5 µL of nuclease-
free water. Thermal cycling was conducted at 95°C for 10 min, followed by 40 cycles of 
94°C for 30 seconds and 60°C for 1 min, and ending with 98°C for 10 min. Gels were 
composed of 1% UltraPure Agarose (Invitrogen) in UltraPure Tris/Borate/EDTA (TBE) 
Buffer (Invitrogen), with addition of SYBR Safe DNA Gel Stain (ThermoFisher). 10 µL 
of each PCR sample was loaded, and allowed to run for 30 min at 80 V. Gels were 
visualized under ultraviolet (UV) light in the UV Transilluminator BioDoc-It System 
Model M-26 (Avantor). 
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ELISA Cytokine Analysis 
 To assess TNFα and IL10 expression in activated human macrophages to confirm 
M1 and M2 polarization respectively, ELISAs were conducted using the Human TNFα 
ELISA MAX Standard Set and Human IL-10 ELISA MAX Standard Set and associated 
protocols (BioLegend). Assay diluent (BioLegend) was used as the zero standard. The 
250 pg/mL top standards were diluted with six two-fold serial dilutions in order to 
generate standard curves for each cytokine. Computer-based curve-fitting software was 
used to generate the standard curve with concentration on the x-axis and absorbance on 
the y-axis. 
All samples were plated in triplicate. The final absorbance of each sample was 
calculated as the absorbance at 570 nm subtracted from the absorbance at 450 nm. The 
concentration of TNFα and IL-10 in each sample was calculated based on the standard 
curve equations generated for each standard. 
  
Identifying Gene Candidates for “AND” and “NOT” Gates 
In order to identify genes that are M1-specific and M2-specific, the Immune 
Oriented Prediction of Clinical Outcomes from Genomics (iPRECOG) Signature Matrix 
was used (Stanford University, 2019). This database quantifies gene expression from 22 
different immune cell phenotypes, including M1 and M2 macrophages, with gene 
expression validated using the CIBERSOFT method (Newman et al., 2015). The database 
was analyzed to select candidate genes for “AND” and “NOT” gates. Expression of 
 24 
candidate genes expressed in M1 and M2 human macrophages was assessed using qPCR 
following the aforementioned protocol. 
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RESULTS 
 
Murine Macrophage Polarization 
 In order to confirm successful M1 and M2 polarization, qPCR was conducted to 
compare gene expression of iNOS and ARG1 in RAW264.7 cells treated with different 
conditions. Using the Pfaffl method for relative quantification of gene expression allows 
for a ratio comparison of the change in gene expression relative to a baseline for different 
treatment conditions. qPCR Results are shown in Table 1 and 2.  
 
Table 1. Relative ARG1 expression in RAW264.7 cells that have been activated to 
become polarized macrophages with different treatment conditions.  
 
 
Table 2. Relative iNOS expression in RAW264.7 cells that have been activated to 
become polarized macrophages with different treatment conditions.  
 
 
Human Macrophage Polarization 
 In order to confirm successful M1 and M2 polarization, three tests were 
conducted. Regular PCR was conducted to confirm gene expression of CXCL11 in THP-
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1 cells treated with LPS and IFNγ. An ELISA for TNFα was conducted to further 
confirm TNFα expression in THP-1 cells treated with LPS and IFNγ, and an ELISA was 
also conducted for IL-10 to confirm its expression in cells treated with IL-4 and IL-13.  
qPCR was conducted to confirm elevated gene expression of IL-10 in THP-1 cells treated 
with IL-4 and IL-13. PCR Results are shown in Figure 7, ELISA results are shown in 
Figure 8 and Figure 9, and qPCR results are shown in Table 3 and Figure 10.  
 
 
 
Figure 7. CXCL11 expression is strongest in THP-1 cells treated with LPS and 
IFNγ, or in M1 polarized macrophages.   CXCL11 is a marker for M1 macrophages 
and is not highly expressed in M2s (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012).  
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Figure 8.  ELISA result for TNFα expression in THP-1 cells that have been 
activated to become macrophages with different treatment conditions. TNFα 
expression is the highest in cells treated with IFNγ and LPS, or M1 polarized 
macrophages. TNFα is an M1 marker.  
 
 
 
 28 
 
Figure 9. ELISA result for IL-10 expression in THP-1 cells that have been activated 
to become macrophages with different treatment conditions. IL-10 expression is the 
highest in cells treated with IL-4 and IL-13. IL-10 is an M2 marker.  
 
 
Table 3. Relative IL-10, an M2 marker, expression in THP-1 cells that have been 
activated to become polarized macrophages with different treatment conditions.  
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Identification of “AND” and “NOT” Gates 
Seven potential “NOT” gate candidates and four potential “AND” gates were 
found in the iPRECOG database. “AND” gate gene candidates are listed in Table 4, and 
“NOT” gate candidates are listed in Table 5. 
 
Table 4. Genes upregulated in M2s and expressed at low levels in M1s, identified 
using iPRECOG data (Stanford University, 2019).  
 
 
 
Table 5. Genes upregulated in M1s and expressed at low levels in M2s, identified 
using iPRECOG data (Stanford University, 2019).  
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Testing Gene Candidates from the iPRECOG Database 
 
 The genes for dipeptidase 2 (DPEP2), histamine receptor H1 (HRH1), and Spi-B 
transcription factor (SPIB) were randomly selected to test their expression levels in M1 
and M2 human macrophages prepared from the THP-1 cell line, in order to reproduce the 
results displayed in the iPRECOG database. qPCR results are displayed in Tables 6, 7, 
and 8. 
 
Table 6. Relative DPEP2 expression levels in polarized macrophages prepared from 
the THP-1 cell line.1 
 
1 Gene expression levels were obtained by conducting qPCR. According to the iPRECOG 
database, DPEP2 is upregulated in M2s (Stanford University, 2019). 
 
Table 7. Relative HRH1 expression levels in polarized macrophages prepared from 
the THP-1 cell line.1 
 
1 Gene expression levels were obtained by conducting qPCR. According to the iPRECOG 
database, HRH1 is upregulated in M2s (Stanford University, 2019). 
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Table 8. Relative SPIB expression levels in polarized macrophages prepared from 
the THP-1 cell line. 
 
1 Gene expression levels were obtained by conducting qPCR. According to the iPRECOG 
database, SPIB is upregulated in M1s (Stanford University, 2019). 
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DISCUSSION 
 
 The goal of this research was to improve the specificity of the existing 
macrophage sensor, by identifying genes specific to the M1 and M2 phenotypes so that 
they could be implemented as Boolean logic gates. In summary, macrophage polarization 
into M1 and M2 phenotypes was accomplished for RAW264.7 and THP-1 cells. For both 
cell lines, M2 polarization was best achieved through combination IL-4 and IL-13 
cytokine treatment. However, for the RAW264.7 cell line, M1 polarization was best 
accomplished with the use of IFNγ alone, whereas for the THP-1 cell line, M1 
polarization was best accomplished with combination treatment of IFNγ and LPS. 
Finally, four potential “AND” and seven potential “NOT” gate targets were identified 
using the iPRECOG database (Stanford University, 2019). However, when expression of 
these genes was assessed in M1 and M2 macrophages activated from the THP-1 cell line, 
gene expression levels did not always correspond with gene expression levels provided in 
the iPRECOG database. 
 
RAW264.7 Cell Line  
 The RAW264.7 macrophage cell line can be challenging to manage. Because of 
the fast growing nature of these macrophage cells featuring an 11 hour doubling time, the 
cells must be passaged frequently (Sakagami et al., 2009). However, the cells also grow 
best when plated at a subcultivation ratio between 1:3 and 1:5, and therefore should not 
be plated at an extremely low density despite their fast growth rate. Furthermore, the 
macrophage cells are healthiest when they are not too confluent, and therefore should be 
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maintained at a confluence density of around 70%. The cells will grow in clumps, 
particularly when cell culture flasks are becoming too confluent. Thus, it is important to 
constantly monitor the RAW264.7 macrophage cells and culture them at an appropriate 
density. 
 
Macrophage Polarization Methods for RAW264.7  
 Many different activation methods for RAW264.7 were explored before 
concluding that combination IL-4 and IL-13 treatment was the best method for M2 
activation, and IFNγ treatment was the best method for M1 activation. For example, IL-4 
and Il-13 were used alone at a concentration of 25 ng/mL each, TNFα was used at a 
concentration of 100 ng/mL, and LPS was used at a concentration of 200 ng/mL, all for a 
24 hour incubation period (Aalipour et al., 2019). In one experiment where IL-4 and IL-
13 were used separately at a concentration of 25 ng/mL, IL-13 did not induce a high level 
of ARG1 expression in the activated macrophages, as is shown in Figure 10.    
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Figure 10. Relative ARG1 expression in RAW264.7 cells treated with IL-4 alone and 
IL-13 alone compared to untreated cells. IL-4 and IL-13 were both used at a 
concentration of 25 ng/mL. It is expected that IL-4 and IL-13 alone should each induce 
M2 polarization and therefore increased ARG1 expression. 
 
 One might wonder why IL-4 is simply not used without IL-13 to polarize murine 
macrophages into the M2 phenotype, given the greater than 200-fold upregulation of 
ARG1 observed for IL-4 treated cells in Figure 10 compared to the approximately 70-
fold upregulation of ARG1 observed for cells treated in combination in Table 1. First, it 
is important to note that fold-changes in gene expression can not simply be compared 
across qPCR data sets. This is because in each qPCR experiment, gene expression is 
normalized relative to GAPDH expression in that experiment. Though GAPDH 
expression is constant across all cells and is therefore a useful housekeeping gene used in 
all gene expression comparisons, in any given real-time RT-PCR experiment using 
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extracted RNA and subsequently synthesized cDNA, the numerical data values for 
GAPDH expression will vary slightly. Thus, GAPDH expression is accounted for every 
time in each qPCR experiment, such that results can be normalized for relative gene 
expression within each experiment. Therefore, one can only compare relative gene 
expression across experiments. For example, a conclusion that can be drawn by 
comparing results between experiments is that ARG1 expression was low in TCM-treated 
macrophages compared to IL-4 and IL-13 treated macrophages (see Table 1 and Figure 
10). However, one can not assume that IL-4 used alone induces more ARG1 expression 
than when used in combination treatment with IL-13 without further experimentation and 
data analysis.  
 Furthermore, it has been proven and is widely accepted in the scientific 
community that both IL-4 and IL-13 whether used alone or in combination are successful 
in polarizing macrophages to the M2 state (Sinha, Clements, Ostrand-Rosenberg, 2005). 
Thus, it is premature to conclude that IL-13 is ineffective in activating M2s, and further 
experimentation must be done in order to do so.  
 Furthermore, TNFα and LPS were used as treatments to induce the M1 
phenotype. TNFα was unsuccessful in inducing iNOS expression, and in fact, produced 
similar iNOS expression levels as cells treated with the IL-4 and IL-13 combination. In 
one experiment, the fold induction for iNOS expression in cells treated with TNFα was 
2.4, and 1.5 for cells treated with a combination IL-4 and IL-13. On the other hand, LPS 
seemed to induce markers of both the M1 and M2 phenotype.  
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 LPS actually caused the largest induction in iNOS expression across all treatment 
types—even greater than IFNγ. LPS caused a 2,3090.3 fold induction in iNOS 
expression, while in the same experiment, IFNγ only caused a 29.4 fold induction. 
However, LPS also triggered a 9.25 fold induction in ARG1 expression in the same 
experiment, suggesting that the LPS-activated macrophages expressed features of both 
M1s and M2s. LPS is a proinflammatory endotoxin released by Gram-negative bacteria, 
and is commonly used in the scientific community to induce M1 polarization (Martinez 
& Gordon, 2014). Thus, further experiments need to be conducted in order to create a 
protocol for M1 polarization of RAW264.7 cells using LPS. For example, perhaps a 
shorter incubation time with LPS will induce only M1 features. An alternative 
explanation for an upregulation of M1 and M2 markers in LPS-activated macrophages 
lies in the idea that the M1 and M2 dichotomy does not actually exist, and that all 
macrophages have features of M1 and M2 cells to different extents (Martinez & Gordon, 
2014).  
 It was hypothesized that TCM would induce ARG1 expression or an M2-like 
phenotype, however, this was not observed. Based on this study, TCM prepared in this 
manner does not seem to be an effective M2 polarization technique.  
 
Human Monocyte Cell Lines 
 Human monocyte cell lines are challenging to manage. Initially, the U-937 cell 
line was cultured in addition to THP-1 cells (ATCC). Polarization was also attempted 
with U-937 cells (Sharp, 2013). However, the U-937 cell line proved to be exceedingly 
 37 
difficult to polarize. The cells seemed to be sensitive to the addition of PMA and 
cytokines, which were causing cell death. Since the THP-1 cells were easier to work with 
in regards to polarization, they were chosen for the purpose of establishing polarization 
protocols. 
 
Macrophage Polarization Methods for THP-1  
 While M2 polarization was simply accomplished with use of IL-4 and IL-13, M1 
polarization was attempted in three different ways before concluding that 4-hour 
incubation with LPS and IFNγ was most effective for M1 polarization. Initially, LPS was 
added to THP-1 cells for a 24-hour incubation period. However, this resulted in cell death 
by the end of the incubation period. Therefore, in subsequent attempts, THP-1 cells were 
incubated with LPS for just 4 hours, and it was noted that this shorter incubation period 
did not impact cell survival. Though PCR results as shown in Figure 7 indicate that M1 
polarization was best accomplished by combined treatment of LPS and IFNγ, the ELISA 
result for TNFα as shown in Figure 8 as well as scientific literature suggest that LPS 
alone is enough to induce M1 polarization (Stossi, Madak-Erdogan, & Katzenellenbogen, 
2012). It should be noted that PCR was chosen to check for CXCL11 expression rather 
than qPCR for no particular reason other than the availability of materials. Furthermore, 
use of ELISAs is a commonly accepted method for verifying human macrophage 
polarization (Stossi, Madak-Erdogan, & Katzenellenbogen, 2012).  
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 “AND” and “NOT” Gate Gene Candidates from the iPRECOG Database  
 qPCR data for expression levels of DPEP2 and SPIB in M1 and M2 polarized 
macrophages (see Tables 6 and 8) was unexpected, as it did not correspond with relative 
gene expression levels denoted in the iPRECOG database (see Tables 4 and 5). 
According to iPRECOG, DPEP2 should have been upregulated in M2s, and therefore 
could have served as a potential “AND” gate for the macrophage sensor, and SPIB 
should have been upregulated in M1s, and therefore could have served as a potential 
“NOT” gate (Stanford University, 2019). Results obtained from qPCR indicate the 
opposite results, as seen in Tables 6 and 8. However, qPCR results for HRH1 expression 
levels as seen in Table 7 are consistent with the iPRECOG database, which suggests that 
M2s have higher HRH1 expression levels, as shown in Table 4.   
 First, it is important to note that the iPRECOG data as shown in Tables 4 and 5 
only indicates relative gene expression in M1 and M2 macrophages. All of the genes 
listed in the database are expressed to some extent in both phenotypes. This explains why 
DPEP2 and SPIB were found to be expressed in both the M1 and M2 phenotypes in this 
experiment (see Table 6 and 8), but does not explain why the relative gene expression 
levels in M1 and M2 phenotypes did not match data found in the iPRECOG database. 
Furthermore, data shown in Tables 6 and 8 may not correspond fully with the iPRECOG 
database because in this experiment, gene expression was assessed using cell lines rather 
than primary cells. The data displayed in the iPRECOG database is based on the analysis 
of primary cells (Newman et al., 2015). Overall, further experimentation with primary 
cells is necessary in order to reproduce the results displayed in the iPRECOG database. 
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Then, candidate genes may be implemented as “AND” or “NOT” gates to add specificity 
to the macrophage sensor. 
 
Limitations  
 The biggest limitation in this study is the use of immortalized  cell lines rather 
than primary cells. Cell lines are commonly used in research, primarily because of their 
cost-effectiveness and ease of use (Kaur and Dufour, 2012). Using cell lines provides 
useful preliminary data which can help paint a picture that is useful in deciding whether 
or not a proposed experiment is feasible. However, ultimately, cells behave differently in 
vivo and feature different characteristics overall. Primary cells are isolated from tissues, 
and retain many of the characteristics and functions which they exhibit in vivo (Kaur and 
Dufour, 2012). Furthermore, the iPRECOG database contains data obtained from 
studying primary cells (Newman et al., 2015). Therefore, in order to reproduce 
conclusions drawn about relative gene expression in M1s and M2s based on the 
iPRECOG database, it is most appropriate to conduct qPCR using RNA extracted from 
primary cells, rather than cell lines. Overall, data from this series of experiments lacks 
full credibility until further experiments are conducting replacing the use of RAW264.7 
and THP-1 cell lines with bone marrow derived monocytes from mice, or macrophages 
derived from human blood (Aalipour et al., 2019).  
 Another limitation of this study is the premise that distinctly polarized M1 and 
M2 macrophages exist in vivo (Martinez & Gordon, 2014). While there are markers for 
M1 and M2 macrophages that are generally accepted in the scientific community, it is 
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much more likely that in vivo, macrophages exhibit different densities of these markers 
depending on their location and role in a given microenvironment (Carmona-Fontaine et 
al., 2017). For example, macrophages that are located in more hypoxic 
microenvironments are more likely to exhibit increased levels of ARG1, an M2 marker 
(Carmona-Fontaine et al., 2017). Thus, macrophages that are closest to a tumor might 
express the highest levels of ARG1, as compared to other “builder” macrophages that are 
also M2s, but exhibit lower levels of ARG1 simply because they are located in a different 
pocket of the tumor microenvironment (Carmona-Fontaine et al., 2017). Maneuvering 
this unclear spectrum of polarization is another reason to use primary cells for further 
studies, rather than cell lines, in order to produce more realistic results. 
 Finally, the macrophage sensor is currently designed for detection of tumors in 
mice and other species where macrophages exhibit ARG1 expression (Aalipour et al., 
2019). Unlike in mice, ARG1 is not expressed in human macrophages, but rather, is 
expressed in human neutrophils (Murray and Wynn, 2011). This means that the current 
macrophage sensor is not actually clinically translatable to humans unless the ARG1 
promoter is replaced with a promoter that is expressed in human macrophages. The 
ARG1 promoter could be replaced with the promoter for a gene identified through the 
iPRECOG database that is upregulated in M2s (see Table 4).  
 
Next Steps 
Isolation of primary monocytes from mouse and human blood is the most 
important next step for this project. Isolation of murine monocytes can be done by 
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utilizing bone marrow from mouse tibias and fibias (Aalipour et al., 2019). Isolation of 
human monocytes can be done from buffy coats or whole blood samples.   
After isolating primary cells, the macrophage polarization protocols that have 
been designed in this thesis should be adapted and tested for polarization accuracy by 
confirming gene expression of iNOS and ARG1 in mouse macrophages, and CXCL11, 
TNFα, and IL-10 in human macrophages. If polarization is successful, then relative gene 
expression of “AND” and “NOT” gene candidates identified from the iPRECOG 
database (see Tables 4 and 5) should be assessed in M1 and M2 human macrophages. 
  
Clinical Translation 
 Due to species to species differences, use of Gluc does pose questions of 
immunogenicity for humans and other organisms (Tannous, 2009). Secreted embryonic 
alkaline phosphatase (SEAP) is a commonly used secreted human reporter protein 
isolated from the human placenta that can be detected in small blood samples (Nilsson et 
al., 2002). Thus, for the purpose of clinical translatability, it would be beneficial to 
replace the Gluc reporter gene with SEAP in order to reduce the risk of immunogenicity 
when introducing the macrophage sensor to human populations. 
The ARG1 promoter is an integral part of the current macrophage sensor, because 
its activation determines when a reporter is produced—in other words, the activation of 
the ARG1 promoter determines the overall specificity of the macrophage sensor. 
However, because the ARG1 promoter is only upregulated in mouse M2s, continued use 
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of the ARG1 promoter poses a long-term challenge in regards to the clinical 
translatability of the project.  
Therefore, it would be beneficial to explore the use of other immune cells for the 
purpose of early cancer detection. For example, since ARG1 is produced in human 
neutrophils rather than macrophages, in vitro testing of a neutrophil sensor could yield 
promising results. Neutrophils could be transfected with the existing plasmid containing 
the ARG1 promoter driving Gluc reporter expression in order to create a neutrophil 
sensor (Aalipour et al., 2019).  
Furthermore, myeloid-derived suppressor cells (MDSCs) stand out as a promising 
replacement for macrophages in this project because human MDSCs also express ARG1, 
and are less prominent players in inflammatory and wound healing environments 
(Vasquez-Dunddel et al., 2013). ARG1 in MDSCs is activated by a different promoter 
than in murine macrophages (Vasquez-Dunddel et al., 2013). In MDSCs, ARG1 is 
activated by the STAT3 promoter instead of the STAT6 promoter (Vasquez-Dunddel et 
al., 2013). Overall, the development of a living immune cell sensor for early cancer 
detection has huge implications for revolutionizing clinical diagnostics.   
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